Hospital-acquired and Ventilator-Associated Pneumonia
Key Points
Key Points
All-cause mortality associated with VAP has been reported to range from 20%–50%.
Serious complications from HAP occur in approximately 50% of patients.
Diagnosis
...iagnosis...
...e 1. Risk Factors for Multidrug-Resistan...
...biologic Methods...
...d IDSA suggest noninvasive sampling wit...
...oninvasive sampling with semiquantitative cult...
...TS and IDSA suggest that patients with suspec...
...omarker...
...ith suspected HAP/VAP, ATS and IDSA recomm...
...ith suspected HAP/VAP, ATS and IDSA re...
...h suspected HAP/VAP, ATS and IDSA recommend usi...
...s with suspected HAP/VAP, ATS and IDS...
Treatment
Treatme...
Initia...
...s with ventilator-associated trach...
...and IDSA recommend that all hospitals regularly...
...IDSA recommend that empiric treatm...
...h suspected VAP, ATS and IDSA recommen...
...d IDSA suggest including an agent active against...
ATS and IDSA suggest including an agent active ag...
...empiric coverage for MRSA is indicated...
...ic treatment that includes coverage for MSSA (a...
...SA suggest prescribing two antipseud...
...SA suggest prescribing one antibiotic active agai...
...patients with suspected VAP, ATS and IDSA...
...tients with suspected VAP, ATS and IDSA suggest a...
...d IDSA recommend that empiric antibio...
...nd IDSA recommend that all hospitals reg...
...ing treated empirically for HAP, ATS a...
...ents with HAP who are being treated empirically a...
...ents with HAP who require empiric cov...
...patients with HAP who are being treated empirical...
...ith HAP who are being treated empirically, ATS a...
...ts with HAP who are being treated empirically...
...with HAP who are being treated empirically, A...
...imizatio...
...patients with HAP/VAP, ATS and IDSA sug...
...led Antibiot...
...s with VAP due to Gram-negative bacilli that are s...
...gen-Specific Therapy...
...IDSA recommend that MRSAHAP/VAP be treated...
...with HAP/VAP due to P. aeruginosa,...
...or patients with HAP/VAP due to P. aeruginosa, A...
...patients with HAP/VAP due to P. aeruginosa who...
...h HAP/VAP due to P. aeruginosa who...
...with HAP/VAP due to P. aeruginosa, ATS and...
...patients with HAP/VAP due to exte...
...HAP/VAP caused by Acinetobacter species, ATS an...
...s with HAP/VAP caused by Acinetobacter species tha...
...d IDSA suggest adjunctive inhaled co...
...th HAP/VAP caused by Acinetobacter spe...
...ts with HAP/VAP caused by Acinetob...
...HAP/VAP caused by a carbapenem-re...
...TS and IDSA suggest adjunctive inhaled colistin. (...
...th VAP, ATS and IDSA recommend a 7-day...
...or patients with HAP, ATS and IDSA recommend a...
...h HAP/VAP, ATS and IDSA suggest that antibio...
...patients with HAP/VAP, ATS and IDSA sug...
...ients with suspected HAP/VAP, ATS and...
.... Recommended Initial Empiric Antibiotic Ther...
...ble 3. Empiric Treatment Options for Susp...